Introduction
Pertussis or whooping cough is an immune-preventable respiratory disease that is still endemic worldwide among infants. This age group is most at risk of morbidity, hospitalization and mortality. Estimates from WHO suggest that in 2008, about 16 million cases of pertussis occurred world-wide, 95% of which were in developing countries, and that about 195 000 children died from the disease (World Health Organization 2010). The best way to prevent this highly contagious disease is to get vaccinated. Two types of pertussis vaccines are available: whole-cell (wP) vaccines based on killed aetiological pathogen (Bordetella pertussis) and acellular (aP) vaccines based on highly purified, selected bacterial components. Although for paediatric population, wP or aP vaccines could be used, for adolescent and adults, only aP vaccine with lower dose of immunogens is recommended to reduce the reactogenicity associated with the other vaccine formulations (World Health Organization 2010) .
The optimal pertussis immunization schedule and the appropriate time for booster dose in a country are normally assessed based on its current epidemiological situation. Because of that, epidemiological surveillance of pertussis is encouraged worldwide. Moreover, the reported shift in the antigenic characteristics of Bord. pertussis circulating strains (Mooi et al. 1998; Hozbor et al. 2009 ) makes such surveillance crucial to evaluate the Keywords disease, pertussis, proteomic, re-emergence, vaccine strains. 1365-2672.2012.05299.x Abstract Aim: To characterize Bordetella pertussis vaccine strains in comparison with current circulating bacteria. Methods and Results: Genomic and proteomic analyses of Bp137 were performed in comparison with other vaccine strains used in Latin America (Bp509 and Bp10536) and with the clinical Argentinean isolate Bp106. Tohama I strain was used as reference strain. Pulse-field gel electrophoresis (PFGE) and pertussis toxin promoter (ptxP) sequence analysis revealed that Bp137 groups with Bp509 in PFGE group III and contains ptxP2 sequence. Tohama I (group II) and Bp10536 (group I) contain ptxP1 sequence, while Bp106 belongs to a different PFGE cluster and contains ptxP3. Surface protein profiles diverged in at least 24 peptide subunits among the studied strains. From these 24 differential proteins, Bp10536 shared the expression of ten proteins with Tohama I and Bp509, but only three with Bp137. In contrast, seven proteins were detected exclusively in Bp137 and Bp106. Conclusions: Bp137 showed more features in common with the clinical isolate Bp106 than the other vaccine strains here included. Significance and Impact of the Study: The results presented show that the old strains included in vaccines are not all equal among them. These findings together with the data of circulating bacteria should be taken into account to select the best vaccine to be included in a national immunization programme. potential impact of bacterial shift on the overall immunity of a population. To control the increasing number of pertussis cases, many countries that do not produce vaccines must import the vaccine doses required to handle the demands of its population. In countries where wP vaccines are still being used, the selection of the vaccine to be imported is a challenge in itself because not all vaccines are formulated with the same strain or the same combination of strains. Latin American countries are using wP vaccines that contain among others the Bord. pertussis strains Bp10536, Bp509 and Bp137. In our previous work, we have characterized the first two vaccine strains (Bp10536 and Bp509) and have observed not only differences between them but also a representative isolate of the currently circulating bacterial population. Bp137 strain has been included in a Brazilian vaccine successfully used in their national vaccination programme for more than 17 years (Pereira et al. 2005) . However, the properties of this strain are scarcely studied. In this work, we present the results obtained from proteomic and genomic studies on this strain and their comparison with those from other vaccine strains. Results from the current clinical isolate Bp106 were also included.
Correspondence

Materials and methods
Bacterial strains and growth conditions
The strains of Bord. pertussis used in this study were Tohama I (Kasuga et al. 1954a,b,c) obtained from the collection of the Pasteur Institute, France, Bp509 (van Hemert 1969) obtained from the Netherlands Vaccine Institute, and Bp10536 (Stainer and Scholte 1970) and Bp137 (Pereira et al. 2005) obtained from the National Administration of Laboratories and Institutes of Health. The last three strains are widely used in wP vaccines in Latin America (Table 1) . The Argentinean clinical isolate, Bp106, which was collected in 2001 from an infant patient residing in Buenos Aires, was also included (Bottero et al. 2007) . The strains and isolates were cultured on Bordet-Gengou agar (BGA, Difco) supplemented with 1% glycerol, Bacto-peptone (Difco) 10 g l )1 and 10% (v ⁄ v) defibrinated sheep blood and incubated at 36°C for 3 days. Then, the bacteria were replated in the same medium for 24 h. Bacterial suspensions prepared from these plates were used for genomic analysis [PCR, sequencing and pulse-field gel electrophoresis (PFGE)].
For proteomic experiments, subcultures were grown in Stainer-Scholte liquid medium (Stainer and Scholte 1970) for 20 h at 36°C until the optical density at 650 nm reached 1AE0.
PCR, sequencing and PFGE
PCR, sequencing and PFGE were performed as previously described Hardwick et al. 2002b; Fiett et al. 2003; Advani et al. 2004; Schouls et al. 2004; Borisova et al. 2007; Bottero et al. 2007) . The sequences of the primers used to amplify and sequence the promoter region of pertussis toxin (ptxP), subunit A of pertussis toxin (ptxA), pertactin (prn), and type 2 (fim2) and type 3 (fim3) fimbriae are given in Table 2 .
The obtained XbaI PFGE profiles were analysed using BioNumerics (Applied Maths, Sint-Martens-Latem, Belgium) software version 3.5. The unweighted pair group method with arithmetic mean (UPGMA) algorithm was used as the clustering method, with a 1% band tolerance and 1% optimization settings with the Dice's coefficient. The band pattern of each strain was verified by visual comparison. PFGE profiles were classified into groups based on a criterion of similarity higher than 82%. 
Serotyping
Serotype analysis was performed using an agglutination assay with monoclonal antibodies against type 2 fimbriae (Fim2; NIBSC, 04 ⁄ 154) and type 3 fimbriae (Fim3, NIBSC, 04 ⁄ 156) according to EU pertstrain group recommendations (http://www.eupertstrain.org). Briefly, 15 ll of bacterial suspension in PBS was mixed on slide with an equal volume of 1 ⁄ 10 dilution of monoclonal antibodies against Fim2 and 1 ⁄ 100 dilution of monoclonal antibodies against Fim3. If the agglutination reaction was obtained with either Fim2, Fim3, or both antibodies, the serotype was defined as Fim2, Fim3 or Fim2,3, respectively. If no reaction was detected, the serotype was defined as untypeable. Autoagglutination was examined with phosphate-buffered saline in parallel with monoclonal antibodies.
Membrane protein enrichment for two-dimensional polyacrylamide gel electrophoresis (2-DE)
Membrane fractions were prepared as described previously (Bottero et al. 2007) . Briefly, Bord. pertussis cells were harvested by centrifugation (10 000 g; 30 min; 4°C) and washed twice with low-salt washing buffer containing 3 mmol l )1 KCl, 68 mmol l )1 NaCl, 1AE5 mmol l )1 KH 2 PO 4 and 9 mmol l )1 NaH 2 PO 4 . The cells were suspended in 10 mmol l )1 Tris-HCl (pH 8AE5) supplemented with phenylmethylsulphonyl fluoride and protease inhibitor cocktail tablets (Roche Applied Science, Buenos Aires, Argentina) and then disrupted with an ultrasonicator (Sonics & Materials, Inc., Danbury, CT, USA). DNase and RNase (20 lg ml )1 each) were added to the cell suspension, and the mixture was incubated at 37°C for 1 h. The unbroken cells were removed by centrifugation (12 000 g; 30 min; 4°C), and the supernatant was retained. Total membrane proteins were then collected by centrifugation (30 000 g, 1 h; 4°C) and resuspended in 7 mol l )1 urea, 2 mol l )1 thiourea, 10% isopropanol and 2% Triton X-100. Membrane proteins were divided into aliquots and stored at )20°C.
Sample preparation, 2-DE and protein identification were repeated at least four times for each strain.
Protein quantification
Protein concentrations were determined by the Bradford's method (Bradford 1976) with bovine serum albumin (Sigma) as a standard.
2-DE
The method previously described by Bottero et al. (2007) was followed. Seven-centimetre Immobiline DryStrip (IPG, pH 4-7; Amersham Biosciences) dissolving 200 lg of the membrane proteins in a volume of 125 ll of rehydration buffer (7 mol l )1 urea, 2 mol l )1 thiourea, 10% isopropanol and 2% Triton X-100) plus 1AE25 ll 28% dithiothreitol (DTT), 0AE62 ll 0AE5% ampholyte (pH 4AE0-7AE0 [Amersham]) and 0AE01% bromophenol blue was rehydrated overnight at room temperature. Three preset programmes were executed with slight modifications so that the focusing conditions consisted of the conditioning step, voltage ramping and final focusing. After IEF, the strips were equilibrated in 50 mmol l )1 Tris buffer (pH 8AE8) containing 6 mol l )1 urea, 2% sodium dodecyl sulphate, 30% glycerol and 1% DTT, followed by another 1h equilibration step with the same buffer supplemented with 4AE5% iodoacetamide. SDS-PAGE was performed according to (Laemmli 1970 ) with a 12AE5% resolving polyacrylamide gel without a stacking gel. Separation in the second dimension was carried out at 40 V at 4°C until the running dye reached the bottom of the gel.
Proteins were visualized using a colloidal Coomassie staining method (http://prospector.ucsf.edu) with the modifications described previously (Bottero et al. 2007) . A gel image was captured in a UVP Bioimaging system Epi Chemi3 Darkroom with a Hamamatsu Photonic systems camera, model 1394 C8484-51-03G, controlled by Labworks image acquisition and analysis software version 4.6.00.0. The 8-bit grey-scale tif files obtained were later processed with the Image Master 2D Platinum software ver. 6.0 (GE Heathcare Argentina S.A., CABA, Argentina).
MALDI-TOF-MS analysis and database search
Coomassie-stained spots were excised from 2-DE gels for tryptic in-gel digestion and MALDI-TOF-MS with an Ultraflex (Bruker) (Bottero et al. 2007) . Peptide mass fingerprint (PMF) data were searched against the NCBI database in MASCOT server (http://www.matrixscience.com) for sequence match. The MASCOT search parameters were as follows: (i) species, bacteria (eubacteria); (ii) allowed number of missed cleavages (only for trypsin digestion), 1; (iii) variable post-translational modification, methionine oxidation; (iv) fixed modification, carbamidomethylation; (v) peptide tolerance, ±50 ppm; (vi) peptide charge, +; and (vii) monoisotopic peptide masses that were used to search the database, allowing a molecular mass range for 2-DE analyses of ±15%. Only significant hits as defined by MASCOT probability analysis were considered. Prediction of protein localization was carried out using a PSORTb.2, PSORTb.3 algorithm available at http:// psort.nibb.ac.jp.and Proteome Analyst (PA) (Lu et al. 2004) .
Results
Genotypic analysis
Chromosomal DNA samples from Bp137 and two other vaccine strains (Bp10536 and Bp509) used in some Latin America countries were digested with XbaI and examined by PFGE. The profiles obtained were compared with that from the reference strain Tohama I (Fig. 1a) . The profiles were distributed in three groups classified according to a criterion of similarity higher than 80%. The vaccine strain Bp137 grouped with Bp509 in PFGE group III. The similarity between these strains was 83%. Group I included Bp10536, and group II was composed of the Japanese vaccine strain Tohama I.
The representative isolate Bp106 collected after the introduction of a massive vaccination programme in Argentina is clearly separated from vaccine strains as we previously reported (Bottero et al. 2007) .
Regarding the genotypification of well-known polymorphic sequences described for virulence factors of Bord. pertussis, vaccine strains Bp137 and Bp509 present pertussis toxin promoter ptxP2 and the allele fim2-2. These genotypes are different from those of the other vaccine strains (Fig. 1b) .
In contrast, the representative clinical isolate Bp106 contained ptxP3, ptxA1, prn2, fim2-1 and fim3-B alleles. In fact, we observed this genotype in the majority of the current members of our collection of circulating clinical isolates (data not shown). Regarding the fim2 and fim3 alleles, 97% of the collection, including the Bp106 representative strain, is fim2-1 and 76% has the variant B for the fim3 allele. In relation to the fim3 allele, the vaccine strains included in our study have the variant A.
The Fim serotypes are Fim2 for Tohama I strain and Fim2,3 for Bp10536, Bp137 and Bp509. In our study, the Fim serotype for Bp106 and for 97% of clinical isolates of our collection was Fim3.
Proteomic analysis
We characterized Bp137 strain by proteomic analysis and compared its surface proteome with the proteomes of the other strains previously reported but repeated here (Bottero et al. 2007 ; Supporting Information, Fig. S1 ). In the analysis, we also included the data of human and murine immunoproteomes already performed (Altindis et al. 2009; Zhu et al. 2010; Tefon et al. 2011) .
The 2-DE profile of Bp137 revealed more than 90 protein spots from which 50 proteins were successfully identified (Fig. 2) . For this work, we have repeated the 2-DE of surface proteins of the other four strains (Bp10536, Bp509, Tohama I and Bp106). In all instances, we have confirmed previously published data, but in addition, we have identified more spots (64 spots in total). Of the total identified peptide subunits, 12 were predicted to be associated with the external membrane ⁄ extracellular localization, ten had periplasmic localization, nine had cytoplasmic membrane localization, eight had an unknown or undefined origin and 25 had a cytoplasmic localization (Table 3) . As observed for the other vaccine strains, some of the proteins separated by 2-DE were present as multiple spots exhibiting variability in pI values (horizontal spot patterns, Fig. 2 ). Charge variants included the following proteins: EF-Tu, 60-kDa chaperonin, outer membrane porin protein precursor, serum resistance protein and serine protease. These may represent natural isoforms or an artefact caused by sample preparation or 2-DE.
From the proteins identified by MALDI-TOF-MS, 14 are involved in small-molecule metabolism (BP2360, BP0277, BP2439, BP2386, BP3288, BP3125, BP0995, BP0379, BP3215, BP1126, BP0844, BP1499, BP0843 and BP0047), seven are associated with macromolecule biosynthesis and degradation (BP2434, BP0007, BP3642, BP2361, BP1420, BP1455 and BP2470), 15 are classified in the category cell structure (BP1146, BP1296, BP3405, BP0840, BP1440, BP3862, BP0943, BP2513, BP2755, BP3150, BP1630, BP2750, BP3559, BP3077 and BP1485), 14 are associated with cellular processes (BP3757, BP1487, BP3322, BP0965, BP3495, BP1285, BP2761, BP3794, BP2747, BP3552, BP1774, BP2235, BP2499 and BP2744), two have general regulatory roles (BP2483 and BP2435), three are associated with phages, transposons and pathogenicity islands (BP2667, BP3494 and BP1054) and, finally, six have unknown function (BP3441, BP2196, BP3128, BP3515, BP2964 and BP1203) according to Riley categories (Riley 1993) . Twenty of the 64 identified proteins were not detected in at least one of the strains studied, and four proteins were detected only in the local isolate Bp106 (Table 3) . Tohama I and Bp509 have very similar protein profiles with only one differential subunit peptide (spot 10). However, these two strains share the expression of only three of the 24 differential proteins with Bp137. Interestingly, we note that seven of 24 peptide subunits were expressed exclusively by the vaccine strain Bp137 and the clinical isolate Bp106. Peptide subunit Bp2235 (spot53), a potential protein of type III secretion system (TTSS), belongs to this group of seven subunits. Two other proteins identified only in Bp106 and Bp137, but not detected in the rest of the vaccine strains, are BP3150 and BP1630, assigned to polysaccharide biosynthesis and capsule biosynthesis (spot 41 and spot 42, respectively, in Bp137).
Human immunoproteomic data recently published (Zhu et al. 2010 ) include 16 of the 64 polypeptides here identified, indicating that they are immunogenic (Table 3) . Other ten were detected to be reactive against murine immune serum. Five of them were reactive against both sera. Three of the five are present in all the strains here included and correspond to well-known antigens of Bord. pertussis: 60-kDa chaperonin (spot 14), pertactin (spot 19) and serum resistance protein (spot 32) (Altindis et al. 2009; Zhu et al. 2010; Tefon et al. 2011) (Table 3) . Other proteins such as BP1285, BP3642 and BP0844 are among the differential proteins here detected.
Discussion
Here, we showed that the PFGE of the Bord. pertussis strain Bp137 and two other strains included in wP vaccines in Latin America were distributed in three groups classified according to a criterion of similarity higher than 80%. Although this observation of the vaccine strain PFGE profiles is similar to that previously reported in other countries (Caro et al. 2005) , it is still important for our region. The current PFGE classifies strains that were not studied before and that are currently included in the national immunization schedules of Latin American countries (e.g. the Brazilian vaccine strain Bp137 and strain Bp10536, which is included in vaccines used in Argentina). The representative isolate Bp106, collected after the introduction of generalized vaccination in Argentina, is clearly separated from vaccine strains as we previously reported (Bottero et al. 2007) . (10) Yes (10) Yes (10) 33592538 bp1440
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Gene loci are named according to NCBI (http://www.ncbi.nlm.nih.gov/). àProtein localization is as predicted by PSORT (http://psort.nibb.ac.jp).
As expected, the above-mentioned Bord. pertussis wP vaccine strains contain the characteristic ptxA, prn and fim3 gene alleles of the old Bord. pertussis strains (Fig. 1b ) (Cassiday et al. 2000; Gzyl et al. 2001; Hardwick et al. 2002a; Fiett et al. 2003) . The vaccine strains Bp137 and Bp509, however, present different characteristics from those of the other vaccine strains: pertussis toxin promoter ptxP2 and the allele fim2-2 instead ptxP1 and fim2-1. The ptxP2 allele was found in the Netherlands at a frequency of 43% and in the United States at 29% during the prevaccination period. In the Netherlands, this allele was also detected during the 1999-2000 period, but at a very low frequency (0AE003%). Bart et al. (2010) showed that strains that harbour this ptxP2 allele represented a distinct lineage that diverged from other strains relatively early in the evolutive history of Bord. pertussis. The ptxP2 and also ptxP1 strains are nearly completely replaced in the late 1990s by the ptxP3 strains. In the Netherlands, the increase in the frequency of ptxP3 strains was associated with the resurgence of pertussis. The ptxP3 strains produced more Ptx than the ptxP1 strain, and epidemiological data suggest that ptxP3 strains are more virulent. The ptxP3 strains have spread worldwide, being the predominant allele in our country Bart et al. 2010) .
Regarding circulating bacteria, we observed that Bp106, as well as the majority of the current members of our collection, contains ptxP3, ptxA1, prn2, fim2-1 and fim3-B alleles (data not shown). The replacement of ptxP1, ptxA2 or ptxA4, prn1 or prn7 strains by ptxP3, ptxA1 and prn2 strains in recent times is a global phenomenon that has been observed in other countries Kallonen and He 2009; Mooi 2010; Advani et al. 2011) .
Regarding the fim2 allele, 97% of the collection, including the Bp106 representative strain, is fim2-1. This finding agrees with observations made in the UK, where fim2-1 has been the prevalent allele since 1920, and in the Netherlands, where it has been the prevalent allele since 1965 Packard et al. 2004) . In relation to the fim3 allele, vaccine strains included in our study have the variant A, which was found in 24% of the isolates of our collection. The representative local strain, Bp106, has the allele B, similar to 76% of the circulating bacteria. This finding agrees with results from Finland prior to 1999, Canada prior to 1990 and Russia prior to 1969, as all isolates in those countries at those times contained the variant A. Isolates obtained from those countries after those years contained the predominant allele B (Tsang et al. 2004; Kallonen and He 2009) .
The Fim serotypes are Fim2 for Tohama I strain and Fim2,3 for Bp10536, Bp137 and Bp509. In our study, the Fim serotype for Bp106 and for 97% of clinical isolates was Fim3. The serotype for these circulating bacteria correlated with observations in other populations where Fim3 is the most frequent (Tsang et al. 2004; Heikkinen et al. 2008; Kallonen and He 2009; Kurova et al. 2010; Zhang et al. 2010; Advani et al. 2011) .
Regarding the proteomic analysis here performed, the 2-DE profile of Bp137 revealed more than 90 protein spots from which 50 proteins were successfully identified (Fig. 2) . Sixteen polypeptides from the total identified seem to be immunogenic in humans as it was recently published (Zhu et al. 2010) .
Comparative analysis of the proteomes showed that Bp137 and Bp106 present seven proteins that are not detected in the other strains. One of these seven proteins is BP2235, which is a potential protein of TTSS (spot 52). This result is striking because previously we found that the TTSS is expressed in bacteria that have recently been in contact with the host, whereas in laboratory-adapted vaccine strains, this expression would not occur (Gaillard et al. 2011) . In contrast to those findings, here we observed the expression of TTSS components in the vaccine strain Bp137, even when this strain is adapted to growth in laboratory conditions. This result suggests that the expression of TTSS in this strain is governed by a different regulatory mechanism than in other vaccine strains. Whatever the molecular mechanism, whose identification is not within the scope of this work, the expression of TTSS components in Bp137 is a desirable feature in a vaccine strain, not only because the TTSS is immunogenic but also because it shares a property with circulating clinical isolates (Fennelly et al. 2008; Medhekar et al. 2008; Zongfu Wu et al. 2008) .
Two other proteins identified only in Bp106 and Bp137 but not detected in the rest of the vaccine strains are BP3150, which is assigned to polysaccharide biosynthesis, and BP1630, which is assigned to capsule biosynthesis (spot 41 and spot 42, respectively, in Bp137). Bacterial capsules allow pathogens to evade host defences. The expression of capsule proteins in these strains, therefore, could indicate the need to overcome the host immune response induced by vaccination.
Our results show that, among the vaccine strains studied here, the strain Bp137 is the one that shares the highest number of proteins detected in the surface proteome with the representative circulating bacteria Bp106. Interestingly, some of these common proteins have immunogenic properties. Based on these results and taking into account the previous reports showing that phenotypic and genotypic divergence between strains could have an impact in protection (King et al. 2001; Bottero et al. 2007) , we suggest that vaccines containing Bp137 could be appropriate to improve the control of pertussis in our region.
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